Guidetti, F.; Arribas, A.J.; Sartori, G.; Spriano, F.; Barnabei, L.; Tarantelli, C.; Von Roemeling, R.; Martinez, E.; Zucca, E.; Bertoni, F.
Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors. J. Clin. Med. 2023, 12, 399.
https://doi.org/10.3390/jcm12020399
AMA Style
Guidetti F, Arribas AJ, Sartori G, Spriano F, Barnabei L, Tarantelli C, Von Roemeling R, Martinez E, Zucca E, Bertoni F.
Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors. Journal of Clinical Medicine. 2023; 12(2):399.
https://doi.org/10.3390/jcm12020399
Chicago/Turabian Style
Guidetti, Francesca, Alberto J. Arribas, Giulio Sartori, Filippo Spriano, Laura Barnabei, Chiara Tarantelli, Reinhard Von Roemeling, Elizabeth Martinez, Emanuele Zucca, and Francesco Bertoni.
2023. "Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors" Journal of Clinical Medicine 12, no. 2: 399.
https://doi.org/10.3390/jcm12020399
APA Style
Guidetti, F., Arribas, A. J., Sartori, G., Spriano, F., Barnabei, L., Tarantelli, C., Von Roemeling, R., Martinez, E., Zucca, E., & Bertoni, F.
(2023). Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors. Journal of Clinical Medicine, 12(2), 399.
https://doi.org/10.3390/jcm12020399
